Enzene Biosciences
Enzene Biosciences is an Indian CDMO using its proprietary EnzeneX® fully-connected continuous manufacturing platform to produce monoclonal antibodies and biosimilars at substantially lower costs than batch methods, serving global pharma and biotech clients from facilities in India and the US.
- Company typePrivate
- Founded2019
- HeadquartersPune, India
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
What Enzene Biosciences does
Enzene Biosciences is a contract development and manufacturing organization (CDMO) headquartered in Pune, India, specializing in biologics production through a proprietary continuous manufacturing platform. Founded in 2019 as a subsidiary of Alkem Laboratories Ltd. (one of India's top five pharmaceutical companies), Enzene operates dual manufacturing facilities in Pune and Hopewell, New Jersey, serving global pharmaceutical and biotech clients. The company's core technology is the EnzeneX® fully-connected continuous manufacturing (FCCM) platform, which integrates intensified perfusion using alternate tangential flow (ATF) with automated multi-column chromatography to enable continuous production of monoclonal antibodies and other complex biologics. The company describes itself as a CIDMO (Continuously Innovative Development & Manufacturing Organization).
The EnzeneX® platform delivers substantial cost and productivity advantages compared to traditional fed-batch manufacturing: monoclonal antibody production costs below $40 per gram versus $150-$300 per gram for batch processes and $80-$100 per gram for competing continuous methods, up to 10x volumetric productivity improvements, and 50-80% processing cost reductions. The company has commercialized four monoclonal antibodies using this technology, including pertuzumab for HER2-positive breast cancer, and offers a portfolio of biosimilars (Adalimumab, Bevacizumab, Cetuximab, Ranibizumab) available for licensing. The platform is supported by process analytical technology (PAT), high-density perfusion cultures, and collaborations with technology partners such as Sartorius for connected membrane chromatography. Enzene won the 2025 CPHI Pharma Award for Manufacturing Excellence in recognition of the EnzeneX 2.0 platform.
Enzene generates revenue through three primary streams: end-to-end CDMO services spanning discovery through commercial manufacturing, biosimilar licensing arrangements, and specialized animal health biologics manufacturing. The company employs 501-1,000 people and has raised $50 million in funding from Alkem Laboratories, Eight Roads Ventures, and F-Prime Capital in January 2023 to support capacity expansion. The go-to-market is enterprise-focused, targeting emerging biotech companies seeking cost-effective clinical-phase manufacturing capacity, biosimilar developers requiring end-to-end development capabilities, and large pharmaceutical companies pursuing manufacturing optimization. Geographic expansion has been a recent priority, with a new $50 million US facility inaugurated in September 2025 and strategic partnerships extending commercial reach into Europe (ADVANZ PHARMA) and Mexico (Saya Biologics).
Enzene Biosciences firmographics
Firmographics- Name
- Enzene Biosciences
- Legal name
- Enzene Biosciences Ltd.
- Website
- https://enzene.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Enzene Biosciences is an Indian CDMO using its proprietary EnzeneX® fully-connected continuous manufacturing platform to produce monoclonal antibodies and biosimilars at substantially lower costs than batch methods, serving global pharma and biotech clients from facilities in India and the US.
- Ownership category
- akta.pro rank
Enzene Biosciences industry classification
Industry- Product category
- Biologics Contract Manufacturing
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)
- akta.pro secondary industries
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Oncology Biosimilars (HLAAAHAG)
Keywords
Where Enzene Biosciences is headquartered
LocationHeadquarters
- HQ city
- Pune
- HQ country
- India
- HQ region
- Asia
Offices2 records
Markets served
Enzene Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Infrastructure, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- CDMO Services: End-to-end contract development and manufacturing services for biologics, spanning discovery, development, and commercial supply. Services include drug substance manufacturing, drug product manufacturing, tech transfer, and scale-up.
- Biosimilar Licensing: Licensing of proprietary biosimilar products including Adalimumab, Bevacizumab, Cetuximab, Ranibizumab, and Pertuzumab. Enzene provides both products for license and biosimilarity packages for biosimilar development.
- Animal Health Solutions: Specialized biologics manufacturing services for animal health companies, covering discovery, development, and commercialization of veterinary biologics.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Multi-year contract | Monoclonal antibody manufacturing at $40/gram using FCCM technology |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels6 records
Enzene Biosciences product offering
Product offeringCore offering
Enzene Biosciences is a biologics CDMO that provides end-to-end contract development and manufacturing services for monoclonal antibodies, biosimilars, bispecific proteins, and complex biologics. The company leverages its proprietary EnzeneX® Fully-Connected Continuous Manufacturing (FCCM™) platform to deliver cost-efficient drug substance and drug product manufacturing, drug discovery, biosimilar licensing, and animal health biologics solutions to global pharmaceutical and biotech clients.
Differentiator
Problem solved
Functional benefit
Brands
- EnzeneX®: Patented Fully-Connected Continuous Manufacturing™ (FCCM™) platform for biologics production that enables cost reductions to below $40 per gram for monoclonal antibodies.
- CIDMO
Products and services
- CDMO Solutions (Contract Development & Manufacturing) End-to-end CDMO services covering drug discovery, drug substance manufacturing, drug product manufacturing, tech transfer, scale-up, and commercial supply for biologics, biosimilars, and complex proteins, delivered to pharmaceutical and biotech clients globally.
- Drug Discovery Services Drug discovery services including target identification and validation, antibody discovery and engineering, custom reagents, and assay development solutions for pharmaceutical and biotech clients.
- EnzeneX® Continuous Biologics Manufacturing Platform Patented and validated continuous bioprocess manufacturing platform enabling fully-connected continuous manufacturing (FCCM) of biologics using intensified perfusion with alternate tangential flow (ATF), automated multi-column chromatography, and integrated process analytical technology, achieving up to 10x productivity and 50-80% cost reduction.
- Drug Substance Manufacturing Mammalian and microbial drug substance manufacturing services for biologics using the EnzeneX® FCCM platform, including cell line development, process development, and commercial scale-up, offered to global pharmaceutical and biotech clients.
- Drug Product Manufacturing (Sterile Fill & Finish) Sterile fill and finish drug product manufacturing services for biologics, including formulation and drug product development, delivered from EU-GMP compliant facilities.
- Analytical / CMC Services Analytical and Chemistry, Manufacturing and Controls (CMC) services including analytical method development, product characterization, dynamic process screening, bioassay capability, and stability studies for biologics programs.
- Biosimilar Licensing (Products for License) Licensing of proprietary biosimilar products including Adalimumab, Bevacizumab, Cetuximab, Ranibizumab, and Pertuzumab, plus biosimilarity packages for biosimilar development partners.
- Animal Health Biologics Manufacturing Specialized biologics manufacturing services for animal health companies, covering discovery, development, and commercialization of veterinary biologics, with facilities designed to comply with USDA guidance and regulations.
Quantifiable outcome
- Up to 10x increase in volumetric productivity
- +5 more outcomes
Companies that use Enzene Biosciences
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles4 records
Enzene Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Enzene Biosciences partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and support.
- Saya BiologicscorePartnership to develop, manufacture, and distribute biosimilars for bone health in Mexico, targeting osteoporosis. Collaboration aims to enhance access to affordable biologic therapies for millions with bone and joint conditions.
- Virtuosi (Quality Executive Partners, Inc.)supportPartnership with Virtuosi, the world's first IACET-accredited immersive training platform for pharmaceutical manufacturing. Enzene becomes the first Indian company to partner with Virtuosi for developing a globally competitive pharmaceutical workforce. Virtuosi provides VR-based training, digital simulation, and accredited technical curricula for workforce development.
- ADVANZ PHARMAcoreStrategic partnership for commercialization of a proposed biosimilar for a rare disease indication. Enzene provides biologic development and manufacturing expertise while ADVANZ PHARMA contributes market access and commercialization capabilities in Europe. Partnership aligns with Enzene's goal of delivering affordable healthcare and expanding access to rare disease treatments across Europe.
- SartoriussupportCollaboration to evaluate membrane chromatography as an alternative to traditional resin-based downstream processes. Using Sartobind membranes for fully connected purification workflow, demonstrating improvements in product recovery rates, HCP and DNA reduction, aggregate removal, and operational efficiency.
Scale indicators10 records
Recent moves9 records
Expansion highlights6 records
Enzene Biosciences competitors and assessment
Company assessmentOthers
- Sartorius: German bioprocessing equipment and solutions provider with membrane chromatography products used in continuous biologics manufacturing. Enzene's technology integration partner and a key enabling supplier for FCCM workflows.
Direct peers
- WuXi Biologics: China-based global biologics CDMO providing end-to-end discovery, development, and manufacturing services for mAbs and biologics. Competes directly with Enzene in biosimilar and innovator CDMO services globally, including in India and emerging markets.
- Samsung Biologics: South Korea-based global biologics CDMO offering mammalian cell culture drug substance, drug product, and fill-finish services. Most direct large-scale competitor to Enzene in biologics manufacturing outsourcing, with significantly larger capacity.
- AGC Biologics: Global CDMO specializing in mammalian and microbial biologics manufacturing with facilities in the US, Europe, and Asia. Directly comparable mid-size biologics CDMO competing for similar biotech and biosimilar clients.
- Rentschler Biologics: Germany-based biologics CDMO focused on mammalian cell culture manufacturing for clients worldwide. Comparable mid-size player competing in mAb CDMO services, particularly for European biotech clients.
Emerging players
- Mabion: Polish biologics CDMO with focus on biosimilars and mammalian cell culture manufacturing. Smaller-scale European peer competing for similar biosimilar development and manufacturing contracts.
Regional players
- Biocon: India-based biopharmaceutical company with a major biosimilars business and contract manufacturing capabilities. Comparable in Indian biosimilars and biologics manufacturing, competing in similar emerging markets.
- Syngene International: India-based CRO/CDMO offering biologics manufacturing services including mAb development and production. Direct Indian-market competitor and fellow domestic CDMO serving global pharma and biotech clients.
Broad incumbents
- Lonza Group: Swiss-headquartered global CDMO leader with deep biologics manufacturing capabilities including mammalian and microbial platforms. A much larger incumbent competing across the full biologics CDMO value chain where Enzene operates.
- Catalent: US-headquartered global CDMO offering biologics, cell and gene therapy, and fill-finish services. Competes with Enzene in biologics development and manufacturing, with established US commercial supply capabilities.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Enzene Biosciences social profiles
Digital presenceEnzene Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Enzene Biosciences leadership team
Management profileNumber of profiles
Profiles7 records
Enzene Biosciences subsidiaries and ownership
Company hierarchySubsidiaries1 record
Enzene Biosciences funding detail
Funding detailFunding overview
Funding rounds1 record
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Enzene Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Enzene Biosciences
What does Enzene Biosciences do?
Enzene Biosciences is a biologics CDMO that provides end-to-end contract development and manufacturing services for monoclonal antibodies, biosimilars, bispecific proteins, and complex biologics. The company leverages its proprietary EnzeneX® Fully-Connected Continuous Manufacturing (FCCM™) platform to deliver cost-efficient drug substance and drug product manufacturing, drug discovery, biosimilar licensing, and animal health biologics solutions to global pharmaceutical and biotech clients.
Is Enzene Biosciences a public or private company?
Enzene Biosciences is a private company. It is classified as corporate owned and is currently operating.
When was Enzene Biosciences founded?
Enzene Biosciences was founded in 2019. It employs 1,001 to 5,000 people.
Where is Enzene Biosciences based?
Enzene Biosciences is headquartered in Pune, India, in the Asia region.
How does Enzene Biosciences make money?
Three revenue lines are on record. CDMO Services are the primary driver. The others are biosimilar Licensing and animal Health Solutions.
Who are Enzene Biosciences's main competitors?
Sartorius is listed as an others. Direct peers are WuXi Biologics, Samsung Biologics, AGC Biologics and Rentschler Biologics. Mabion is listed as an emerging player. Regional players are Biocon and Syngene International. Broad incumbents are Lonza Group and Catalent.
Does Enzene Biosciences have an API?
No public API is recorded for Enzene Biosciences.
What industry is Enzene Biosciences in?
Enzene Biosciences's product category is Biologics Contract Manufacturing. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 325414 and its SIC code is 2836.